Monday, March 17, 2008

Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.—March 17, 2008—Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced updates to the U.S. Food and Drug Administration (FDA)-approved U.S. Prescribing Information (PI) for Enbrel® (etanercept).

Read the rest of this entry

Posted in Press Releases

Friday, March 14, 2008

Amgen to Present at the 28th Annual Cowen Healthcare Conference and the 11th Annual Lehman Brothers Global Healthcare Conference

THOUSAND OAKS, Calif.—March 13, 2008—Amgen Inc. (NASDAQ: AMGN) will present at the 28th Annual Cowen Healthcare Conference on Tuesday, March 18, 2008 at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:30 a.m. Eastern Time. Amgen will also present at the 11th Annual Lehman Brothers Global Healthcare Conference on Wednesday, March 19, 2008, at the Loews Miami Beach Hotel in Miami, Fla., beginning at 8:00 a.m. Eastern Time.

Read the rest of this entry

Posted in Press Releases

Thursday, March 13, 2008

Amgen Statement on Outcome of ESA ODAC Meeting

THOUSAND OAKS, Calif., (March 13, 2008) – Amgen Inc. (NASDAQ: AMGN) today issued the following statement on the outcome of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting on the benefits and risks of erythropoiesis-stimulating agents (ESAs) in oncology.

Read the rest of this entry

Posted in

Thursday, March 13, 2008

Presentations from FDA ODAC Meeting Held March 13, 2008

On Thursday, March 13, 2008, Amgen presented the benefits and risks of Erythropoiesis-stimulating Agents (ESAs) in cancer patients with anemia due to concomitantly administered chemotherapy at a meeting with the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC).

Read the rest of this entry

Posted in

Thursday, March 13, 2008

Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting

ESAs Provide Important Clinical Benefits to Cancer Patients With Anemia Due to Chemotherapy; Ongoing and Planned Risk Management Will Further Reduce Risks 

THOUSAND OAKS, Calif.—March 13, 2008—Amgen Inc. (NASDAQ: AMGN) will today present the benefits and risks of Erythropoiesis-stimulating Agents (ESAs) in cancer patients with anemia due to concomitantly administered chemotherapy at a meeting with the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC). ESAs provide these patients with the only therapeutic alternative to red blood cell (RBC) transfusions, which have known and uncertain risks.

Read the rest of this entry

Posted in Press Releases